drugset / Trial / NCT03877692

Acute Control of Chronic Hypertension

NCT03877692

Phase 4 Terminated 10 enrolled Albany Medical College
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's history of preexisting hypertension, will be more effective at controlling severe hypertension during pregnancy, compared to the current standard dosing.

Timeline

Start
2019-02-18
Primary completion
2020-07-20
Completion
2020-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Labetalol Small molecule 20 mg Intravenous
Subject Labetalol Small molecule 40 mg Intravenous
Subject Labetalol Small molecule 60 mg Intravenous
Subject Labetalol Small molecule 80 mg Intravenous

Indications